{
    "clinical_study": {
        "@rank": "1543", 
        "arm_group": {
            "arm_group_label": "Avastin regimens", 
            "description": "Patients who are going to receive chemotherapy plus Avastin (bevacizumab)"
        }, 
        "brief_summary": {
            "textblock": "Investigators propose to assess,the safety and tolerability profile (number of participants\n      with adverse events) of bevacizumab (Avastin) when added to chemotherapy as front-line\n      treatment of epithelial ovarian cancer, fallopian tube carcinoma or primary peritoneal\n      carcinoma"
        }, 
        "brief_title": "Observation of Bevacizumab Plus Front-line Chemotherapy in Patients With Ovarian Cancer", 
        "completion_date": {
            "#text": "March 2015", 
            "@type": "Anticipated"
        }, 
        "condition": "Ovarian Cancer", 
        "condition_browse": {
            "mesh_term": [
                "Ovarian Neoplasms", 
                "Fallopian Tube Neoplasms"
            ]
        }, 
        "detailed_description": {
            "textblock": "In the last decade, clinical studies with bevacizumab (Avastin) in various tumors have shown\n      encouraging results in terms of efficacy/safety. However there is no data generated in Greek\n      population with regards to safety and efficacy of bevacizumab in front line Ovarian Cancer.\n      Two prior  global phase III randomized trials showed that the addition of concurrent\n      bevacizumab to standard chemotherapy and maintenance bevacizumab significantly increased the\n      PFS in patients with advanced ovarian cancer It would be relevant to document the real life\n      clinical data of bevacizumab in combination with chemotherapy (paclitaxel/carboplatin) in\n      Front Line Ovarian Cancer as prescribed by the medical oncologists in Greece."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Written informed consent\n\n          -  Age \u226518 years\n\n          -  Histologically confirmed advanced stage III (suboptimally debulked >1cm of residual\n             disease) or stage IV ovarian cancer fallopian tube carcinoma or primary peritoneal\n             cancer following surgical debulking with the aim of maximal surgical cytoreduction\n\n          -  One or more measurable lesions (\u22651cm in diameter with spiral CT scan or \u22652cm    with\n             conventional techniques) according to RECIST criteria\n\n          -  ECOG performance status \u22642\n\n          -  Adequate haematological, renal and hepatic function\n\n          -  Urine protein <2+ (dipstick)\n\n          -  Life expectancy of >12 weeks\n\n        Exclusion Criteria:\n\n          -  Previous front line treatment for ovarina cancer\n\n          -  Previous radiotherapy to target lesions\n\n          -  Patients with brain metastases and/or cancerous meningitis\n\n          -  Presence or history of other neoplasm except properly treated basal cell skin cancer\n             or in situ cervical carcinoma\n\n          -  Patients participating in interventional clinical trial"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years", 
            "sampling_method": "Probability Sample", 
            "study_pop": {
                "textblock": "Clinics for cancer prevention"
            }
        }, 
        "enrollment": {
            "#text": "200", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "November 3, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01982500", 
            "org_study_id": "CT/12.01"
        }, 
        "intervention_browse": {
            "mesh_term": "Bevacizumab"
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "Ovarian Cancer", 
            "Chemotherapy", 
            "Anti-angiogenic agent", 
            "Bevacizumab", 
            "Front Line"
        ], 
        "lastchanged_date": "November 6, 2013", 
        "location": [
            {
                "contact": {
                    "email": "evamaragoud@gmail.com", 
                    "last_name": "Eva Maragkoudaki", 
                    "phone": "+302810392570"
                }, 
                "facility": {
                    "address": {
                        "city": "Heraklion", 
                        "country": "Greece", 
                        "state": "Crete"
                    }, 
                    "name": "University Hospital of Crete, Dep of Medical Oncology"
                }, 
                "investigator": {
                    "last_name": "Antonia Kalykaki, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Stylianos Kakolyris, MD"
                }, 
                "contact_backup": {
                    "last_name": "Nikolaos Xenidis, MD"
                }, 
                "facility": {
                    "address": {
                        "city": "Alexandroupolis", 
                        "country": "Greece"
                    }, 
                    "name": "University General Hospital of Alexandroupolis, Dept. of Medical Oncology"
                }, 
                "investigator": {
                    "last_name": "Stelios Kakolyris, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "nikos251@yahoo.gr", 
                    "last_name": "Nikos Fytrakis", 
                    "phone": "2107715690"
                }, 
                "facility": {
                    "address": {
                        "city": "Athens", 
                        "country": "Greece"
                    }, 
                    "name": "Air Forces Military Hospital of Athens"
                }, 
                "investigator": {
                    "last_name": "Nikos Kentepozidis, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Stylianos Giassas, MD"
                }, 
                "facility": {
                    "address": {
                        "city": "Athens", 
                        "country": "Greece"
                    }, 
                    "name": "\"IASO\" General Hospital of Athens"
                }, 
                "investigator": {
                    "last_name": "Stylianos Giassas, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Nikolaos Ziras, MD"
                }, 
                "facility": {
                    "address": {
                        "city": "Piraeus", 
                        "country": "Greece"
                    }, 
                    "name": "\"Metaxa's\" Anticancer Hospital of Piraeus, 1st Dep of Medical Oncology"
                }, 
                "investigator": {
                    "last_name": "Nikolaos Ziras, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Ioannis Mpoukovinas, MD"
                }, 
                "facility": {
                    "address": {
                        "city": "Thessaloniki", 
                        "country": "Greece"
                    }, 
                    "name": "\"Theagenion\" Anticancer Hospital of Thessaloniki, 2nd Dep of Medical Oncology"
                }, 
                "investigator": {
                    "last_name": "Ioannis Mpoukovinas, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }
        ], 
        "location_countries": {
            "country": "Greece"
        }, 
        "number_of_groups": "1", 
        "official_title": "A Multicentre, Observational Study of Bevacizumab (Avastin) Added to Front-line Chemotherapy in Patients With Stage IIIb, IIIC or IV Epithelial Ovarian Cancer, Fallopian Tube Carcinoma or Primary Peritoneal Carcinoma in Routine Clinical Practice.", 
        "overall_contact": {
            "email": "georgulv@otenet.gr", 
            "last_name": "Vassilis Georgoulias, MD", 
            "phone": "+302810392750"
        }, 
        "overall_official": {
            "affiliation": "Hellenic Oncology Research Group", 
            "last_name": "Antonia Kalykaki, MD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "Greece: National Organization of Medicines", 
            "has_dmc": "No"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "March 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "In this observational study investigators are going to assess standard schedules  in which administration was every 3 weeks", 
            "measure": "Number of Participants with Adverse Events", 
            "safety_issue": "Yes", 
            "time_frame": "Every 3 weeks up to 18 weeks"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01982500"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "In this observational study investigators are going to assess standard schedules in which the disease evaluation was performed every 3 weeks", 
                "measure": "Number of Participants with Response Rate", 
                "safety_issue": "No", 
                "time_frame": "Disease evaluation at Week 3"
            }, 
            {
                "measure": "Percentage of Patients with Progression Free Survival", 
                "safety_issue": "No", 
                "time_frame": "1 year"
            }, 
            {
                "measure": "Patients Overall Survival", 
                "safety_issue": "No", 
                "time_frame": "1 year"
            }
        ], 
        "source": "Hellenic Oncology Research Group", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Hellenic Oncology Research Group", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "March 2012", 
        "study_design": "Observational Model: Cohort", 
        "study_type": "Observational", 
        "verification_date": "November 2013"
    }
}